Exosomes in Regenerative Medicine
What are exosomes and what can they do?
Since the original description of exosomes over 30 years ago, the term has been loosely used for various forms of extracellular vesicle, muddying the field and contributing to the skepticism with which the research has sometimes been met. Exosomes are best defined as extracellular vesicles that are released from cells upon fusion of an intermediate endocytic compartment, the multivehicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes
Exosomes have been explored as a means of treatment when applied to regenerative therapy as their ability to store molecular structures and communicate with other cells helps contribute to healing. Since exosomes that are secreted from fibrocytes contain proteins and microRNA crucial in regulating collagen deposition and treating inflammation, they have been attributed to improving tissue health during wound therapy.
Types of Allografts we offer
The use of exosomes in skin repair and wound healing
Exosomes or extracellular vesicles are utilized because of their excellent therapeutic potential. Improved vascularization, control of inflammation, the rejuvenation of skin from the effects of aging or trauma are some of the benefits that can be derived from the use of exosomes.
Exosomes have shown in many studies to have positive effects on both wound healing and skin repair making them attractive treatment options in regenerative medicine and in the treatment of acute and chronic wounds. In one study, exosomes were shown to have tremendous potential as a noncellular, off-the-shelf therapeutic modality for wound healing.
These peer-reviewed scientific articles all demonstrate the
amazing benefits of using exosomes in regenerative medicine.
Lipids, proteins and nucleic acids are transported to MVBs and onto or into the intraluminal vesicles, which upon fusion of the MVB with the plasma membrane are released as exosomes.
Clinical Studies on the Capabilities of Amniotic Fluid
There are more than 200,000 peer reviewed scientific publications on pubmed and other medical journals with thousands discussing positive outcomes following the use of amniotic ﬂuid in regenerative medicine.
All birth tissue products are obtained from C-section deliveries from normal, full-term pregnancies. Donors that consent to use of their birth tissues are carefully screened prior to the use of their tissues in manufacturing.
Comprehensive medical and social histories of the donors are obtained and tissues are procured, processed, and tested to minimize potential risks of disease transmission to recipients. Infectious disease testing is performed at a certified laboratory in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493.
Each donor is tested for HBsAg (Hepatitis B Surface Antigen), HBcAb (hepatitis B core Antibody), HCV (hepatitis C Antibody), HIV I/II-Ab (Antibody to Human Immunodeﬁciency Virus Types 1 and Syphilis detection test, HIV NAT (HIV Nucleic Acid Test), and HCV NAT (HCV Nucleic Acid Test).
All products are tested post-sterilization to demonstrate the absence of bacterial and fungal pathogens and are non-pyrogenic.